SANTA CLARA, Calif. / Apr 04, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its participation in Analytica 2024, where it will unveil its latest innovations and transformative workflows. Analytica, the premier international trade fair for laboratory technology, analysis, and biotechnology, is scheduled to take place from April 9 to 12 in Munich, Germany.
Visit Agilent at Hall A2, Booth 201, to learn about recently introduced products and solutions enabling key workflows that are revolutionizing laboratories across industries including pharma and biopharma, food and environment, chemical and energy, advanced materials, and molecular biology and cell analysis. Agilent technical experts will be available to share insights into these latest innovations and intuitive workflows.
Agilent will also host several meet-and-greet specialist sessions in the booth.
Agilent subject matter experts will also speak throughout the week at forum sessions. To learn more about Agilent’s complete activities at Analytica 2024 click here. Join us as we bring Great Science to Life!
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$124.17 |
Daily Change: | 2.87 2.37 |
Daily Volume: | 2,048,809 |
Market Cap: | US$35.270B |
May 27, 2025 April 24, 2025 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load